title: Efficacy of oral famotidine and 2 omeprazole formulations for the control of intragastric pH in dogs.
abstract: BACKGROUND
  Little is known about the efficacy of commonly used acid suppressants on intragastric pH in dogs.
  
  
  OBJECTIVE
  To compare the effect of oral famotidine, 2 formulations of omeprazole, and placebo on intragastric pH in dogs with a catheter-free, continuous pH monitoring system.
  
  
  METHODS
  Six healthy adult mixed-breed colony dogs.
  
  
  METHODS
  Utilizing a randomized, 4-way cross over, open-label study, dogs were administered famotidine PO (1.0-1.3 mg/kg q12h), omeprazole tablet (1.5-2.6 mg/kg q24h), omeprazole reformulated paste (RP) (Gastrogard, 1.5-2.6 mg/kg q24h), and placebo for 7 days followed by a 10-day washout period. Radiotelemetric pH capsules were placed with gastroscopy assistance to continuously record intragastric pH for 4 days (days 4-7 of dosing). The percentage of time that intragastric pH was ≥3 and ≥4 was compared among treatment groups using repeated measures of analysis of variance. Tukey's Studentized range test was used to determine which groups were different with α= 0.05.
  
  
  RESULTS
  Mean ± SD percent time intragastric pH was ≥3 and ≥4 was 22 ± 8% and 14 ± 6% for famotidine, 63 ± 14% and 52 ± 17% for omeprazole tablet, 54 ± 17% and 44 ± 18% for omeprazole RP, and 6 ± 6% and 5 ± 5% for placebo. Both omeprazole formulations significantly increased intragastric pH compared with famotidine and placebo, but omeprazole tablet and RP was not significantly different from each other.
  
  
  CONCLUSIONS
  Oral omeprazole tablet and RP provide superior gastric acid suppression to famotidine, and should therefore be considered more effective for the treatment of acid related disorders in dogs.
authors.affiliation: Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, USA.
authors.forename: K
authors.initials: K
authors.lastname: Tolbert
authors.forename: S
authors.initials: S
authors.lastname: Bissett
authors.forename: A
authors.initials: A
authors.lastname: King
authors.forename: G
authors.initials: G
authors.lastname: Davidson
authors.forename: M
authors.initials: M
authors.lastname: Papich
authors.forename: E
authors.initials: E
authors.lastname: Peters
authors.forename: L
authors.initials: L
authors.lastname: Degernes
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000494:pharmacology*; D018592:Cross-Over Studies; D004285:Dogs / Q000378:metabolism*; D015738:Famotidine / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005745:Gastric Acidity Determination / Q000662:veterinary; D005753:Gastric Mucosa / Q000378:metabolism*; D006863:Hydrogen-Ion Concentration / Q000187:drug effects; D008297:Male; D009853:Omeprazole / Q000008:administration & dosage / Q000494:pharmacology*; D013270:Stomach / Q000187:drug effects*; D013686:Telemetry / Q000662:veterinary
chemical_list: D000897:Anti-Ulcer Agents; D015738:Famotidine; D009853:Omeprazole